TY - JOUR
T1 - High grade osteosarcoma of the extremities with lung metastases at presentation
T2 - Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions
AU - Bacci, Gaetano
AU - Rocca, Michele
AU - Salone, Mariacristina
AU - Balladelli, Alba
AU - Ferrari, Stefano
AU - Palmerini, Emanuela
AU - Forni, Cristiana
AU - Briccoli, Antonio
PY - 2008/11/1
Y1 - 2008/11/1
N2 - Background and Methods: Between 1986 and 2001, 162 patients with extremity osteosarcoma and lung metastases at presentation, were treated by neoadjuvant chemotherapy, simultaneous resection of primary and, when feasible, secondary lesions followed by chemotherapy. Results: After neoadjuvant chemotherapy, metastases disappeared in 14 patients, 16 were judged unresectable by both our thoracic surgeons, 132 had primary tumors and lung metastases removed simultaneously. Removal of lung metastases was complete in 123 and incomplete in 9. Histologically lesions were benign in 32 patients. For the 100 patients simultaneously operated with histologically proven lung metastases, 5-year event-free survival (EFS) was 18.9%; 27.4% for the 91 who had a complete resection of pulmonary lesions and entered remission as opposed to none for 9 patients who had incomplete removal of lung nodules. Among these 91, 5-year EFS was significantly higher for patients with monolateral compared to bilateral lesions (27.1% vs. 7.9%, P <0.02) and when only one to three metastatic nodules were present (40.0% vs. 13.3%, P <0.0001). Conclusions: These different results, demonstrate that our treatment had a reasonable survival outcomewhereas other groups continue to have dismal prognosis. More efforts should be made to improve survival by identifying new active agents or novel approaches with cellular molecular targets.
AB - Background and Methods: Between 1986 and 2001, 162 patients with extremity osteosarcoma and lung metastases at presentation, were treated by neoadjuvant chemotherapy, simultaneous resection of primary and, when feasible, secondary lesions followed by chemotherapy. Results: After neoadjuvant chemotherapy, metastases disappeared in 14 patients, 16 were judged unresectable by both our thoracic surgeons, 132 had primary tumors and lung metastases removed simultaneously. Removal of lung metastases was complete in 123 and incomplete in 9. Histologically lesions were benign in 32 patients. For the 100 patients simultaneously operated with histologically proven lung metastases, 5-year event-free survival (EFS) was 18.9%; 27.4% for the 91 who had a complete resection of pulmonary lesions and entered remission as opposed to none for 9 patients who had incomplete removal of lung nodules. Among these 91, 5-year EFS was significantly higher for patients with monolateral compared to bilateral lesions (27.1% vs. 7.9%, P <0.02) and when only one to three metastatic nodules were present (40.0% vs. 13.3%, P <0.0001). Conclusions: These different results, demonstrate that our treatment had a reasonable survival outcomewhereas other groups continue to have dismal prognosis. More efforts should be made to improve survival by identifying new active agents or novel approaches with cellular molecular targets.
KW - Bone sarcoma
KW - Pulmonary metastases
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=55749100652&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55749100652&partnerID=8YFLogxK
U2 - 10.1002/jso.21140
DO - 10.1002/jso.21140
M3 - Article
C2 - 18792969
AN - SCOPUS:55749100652
VL - 98
SP - 415
EP - 420
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
SN - 0022-4790
IS - 6
ER -